Dr Chiara Ciccarese talks to ecancer at ESMO 2024 about data she presented from the randomized phase II TACITO trial.
This looked at faecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma.
The preliminary results of TACITO trial show for the first time the role of FMT in increasing the activity of immune checkpoint inhibitor based therapies in metastatic renal cell carcinoma patients.